Page 29 - Merck Sharp News Today

Pembrolizumab yielded responses in patients with chordoma, desmoplastic small round cell tumors, epithelioid sarcoma, and other rare sarcomas.

TME PHARMA PROVIDES POSITIVE DATA UPDATE ON BEST RESPONSE TO THERAPY WITH FIRST COMPLETE RESPONSE IN GLORIA TRIAL IN GLIOBLASTOMA, BRINGING 50% OF PATIENTS IN EXPANSION ARM TO COMPLETE OR NEAR-COMPLETE RESPONSEBerlin, Germany, July 13, 2023, 08.00 a.m. CEST – TME Pharma N.V. (Euronext Growth Paris: ALTME), a b...

Promising results in a trial of ketamine for severe depression could lead to treatment becoming more affordable in Australia.

While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.

BERLIN--(BUSINESS WIRE)--Regulatory News:TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces a positive clinical update on the best response to therapy, reporting one patient ach...

/PRNewswire/ -- DelveInsights Progressive Supranuclear Palsy Market Insights report includes a comprehensive understanding of current treatment practices,...

In this article, we will discuss value investor Joel Greenblatt’s portfolio, hedge fund returns, and his Magic Formula. You can skip our detailed analysis of Greenblatt’s investment philosophy and his hedge fund’s performance over the years, and go directly to read Joel Greenblatt’s Top 5 Stock Picks. Joel Greenblatt, renowned for his expertise in value […]

In this article, we will discuss value investor Joel Greenblatt’s portfolio, hedge fund returns, and his Magic Formula.

/PRNewswire/ -- DelveInsights KRAS Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging KRAS...

MSD Vietnam inaugurated its new office in Hanoi on July 8.